221 related articles for article (PubMed ID: 8826849)
1. Targeted inhibition of tumour cell growth by a bispecific single-chain toxin containing an antibody domain and TGF alpha.
Schmidt M; Wels W
Br J Cancer; 1996 Sep; 74(6):853-62. PubMed ID: 8826849
[TBL] [Abstract][Full Text] [Related]
2. A bivalent single-chain antibody-toxin specific for ErbB-2 and the EGF receptor.
Schmidt M; Hynes NE; Groner B; Wels W
Int J Cancer; 1996 Feb; 65(4):538-46. PubMed ID: 8621240
[TBL] [Abstract][Full Text] [Related]
3. Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo.
Azemar M; Schmidt M; Arlt F; Kennel P; Brandt B; Papadimitriou A; Groner B; Wels W
Int J Cancer; 2000 Apr; 86(2):269-75. PubMed ID: 10738256
[TBL] [Abstract][Full Text] [Related]
4. EGF receptor and p185erbB-2-specific single-chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins.
Wels W; Beerli R; Hellmann P; Schmidt M; Marte BM; Kornilova ES; Hekele A; Mendelsohn J; Groner B; Hynes NE
Int J Cancer; 1995 Jan; 60(1):137-44. PubMed ID: 7814146
[TBL] [Abstract][Full Text] [Related]
5. Biotechnological and gene therapeutic strategies in cancer treatment.
Wels W; Moritz D; Schmidt M; Jeschke M; Hynes NE; Groner B
Gene; 1995 Jun; 159(1):73-80. PubMed ID: 7607575
[TBL] [Abstract][Full Text] [Related]
6. Synergistic interaction between an anti-p185HER-2 pseudomonas exotoxin fusion protein [scFv(FRP5)-ETA] and ionizing radiation for inhibiting growth of ovarian cancer cells that overexpress HER-2.
Schmidt M; McWatters A; White RA; Groner B; Wels W; Fan Z; Bast RC
Gynecol Oncol; 2001 Feb; 80(2):145-55. PubMed ID: 11161852
[TBL] [Abstract][Full Text] [Related]
7. Construction and functional characterization of scFv(14E1)-ETA - a novel, highly potent antibody-toxin specific for the EGF receptor.
Schmidt M; Vakalopoulou E; Schneider DW; Wels W
Br J Cancer; 1997; 75(11):1575-84. PubMed ID: 9184171
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapy of schwannoma cells in immunocompetent rats with an erbB2-specific antibody-toxin.
Altenschmidt U; Schmidt M; Groner B; Wels W
Int J Cancer; 1997 Sep; 73(1):117-24. PubMed ID: 9334818
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effect of an HER2-specific antibody-toxin fusion protein on human prostate cancer cells.
Wang L; Liu B; Schmidt M; Lu Y; Wels W; Fan Z
Prostate; 2001 Apr; 47(1):21-8. PubMed ID: 11304726
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin-resistant neuroblastoma cells express enhanced levels of epidermal growth factor receptor (EGFR) and are sensitive to treatment with EGFR-specific toxins.
Michaelis M; Bliss J; Arnold SC; Hinsch N; Rothweiler F; Deubzer HE; Witt O; Langer K; Doerr HW; Wels WS; Cinatl J
Clin Cancer Res; 2008 Oct; 14(20):6531-7. PubMed ID: 18927293
[TBL] [Abstract][Full Text] [Related]
11. Transforming growth factor alpha-Pseudomonas exotoxin fusion protein prolongs survival of nude mice bearing tumor xenografts.
Heimbrook DC; Stirdivant SM; Ahern JD; Balishin NL; Patrick DR; Edwards GM; Defeo-Jones D; FitzGerald DJ; Pastan I; Oliff A
Proc Natl Acad Sci U S A; 1990 Jun; 87(12):4697-701. PubMed ID: 2352944
[TBL] [Abstract][Full Text] [Related]
12. Suppression of metastasis formation by a recombinant single chain antibody-toxin targeted to full-length and oncogenic variant EGF receptors.
Schmidt M; Maurer-Gebhard M; Groner B; Köhler G; Brochmann-Santos G; Wels W
Oncogene; 1999 Mar; 18(9):1711-21. PubMed ID: 10208432
[TBL] [Abstract][Full Text] [Related]
13. Replacement of N-terminal portions of TGF-alpha with corresponding heregulin sequences affects ligand-induced receptor signaling and intoxication of tumor cells by chimeric growth-factor toxins.
Schmidt M; Wels W
Int J Cancer; 2002 Jan; 97(3):349-56. PubMed ID: 11774287
[TBL] [Abstract][Full Text] [Related]
14. Human kappa light chain targeted Pseudomonas exotoxin A--identifying human antibodies and Fab fragments with favorable characteristics for antibody-drug conjugate development.
Kellner C; Bleeker WK; Lammerts van Bueren JJ; Staudinger M; Klausz K; Derer S; Glorius P; Muskulus A; de Goeij BE; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
J Immunol Methods; 2011 Aug; 371(1-2):122-33. PubMed ID: 21756911
[TBL] [Abstract][Full Text] [Related]
15. A recombinant form of Pseudomonas exotoxin A containing transforming growth factor alpha near its carboxyl terminus for the treatment of bladder cancer.
Theuer CP; FitzGerald DJ; Pastan I
J Urol; 1993 Jun; 149(6):1626-32. PubMed ID: 8501821
[TBL] [Abstract][Full Text] [Related]
16. Biological activity of a transforming growth factor-alpha--Pseudomonas exotoxin fusion protein in vitro and in vivo.
Heimbrook DC; Stirdivant SM; Ahern JD; Balishin NL; Patrick DR; Edwards GM; Defeo-Jones D; FitzGerald DJ; Pastan I; Oliff A
J Ind Microbiol; 1991 Apr; 7(3):203-7. PubMed ID: 1367127
[TBL] [Abstract][Full Text] [Related]
17. Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor.
Wels W; Harwerth IM; Mueller M; Groner B; Hynes NE
Cancer Res; 1992 Nov; 52(22):6310-7. PubMed ID: 1358432
[TBL] [Abstract][Full Text] [Related]
18. In vivo imaging of immunotoxin treatment using Katushka-transfected A-431 cells in a murine xenograft tumour model.
Pardo A; Stöcker M; Kampmeier F; Melmer G; Fischer R; Thepen T; Barth S
Cancer Immunol Immunother; 2012 Oct; 61(10):1617-26. PubMed ID: 22350071
[TBL] [Abstract][Full Text] [Related]
19. Chemosensitivity testing of oral cancer cells treated with a p185neu-specific agent.
Werkmeister R; Fillies T; Brandt B; Groner B; Weis W; Joos U
Eur J Oral Sci; 1999 Oct; 107(5):338-43. PubMed ID: 10515198
[TBL] [Abstract][Full Text] [Related]
20. Polyethylene glycol-modified chimeric toxin composed of transforming growth factor alpha and Pseudomonas exotoxin.
Wang QC; Pai LH; Debinski W; FitzGerald DJ; Pastan I
Cancer Res; 1993 Oct; 53(19):4588-94. PubMed ID: 8402632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
